Human Antibodies

Volume

30, 4 issues

Latest issue

30:2 online 20 May 2022

Next issue

30:3 scheduled for August 2022

Back volumes

From volume 1, 1990

ISSN print

1093-2607

ISSN online

1875-869X

Aims & Scope

Human Antibodies is an international journal designed to bring together all aspects of human hybridomas and antibody technology, along with factors that modulate host antibody repertoire and effectiveness, such as vaccines, infectious agents, and microbiome. This includes fundamental research, applied science and clinical applications. Emphasis in the published articles is on antisera, monoclonal antibodies, fusion partners, EBV transformation, transfections, in vitro immunization, defined antigens, tissue reactivity, scale-up production, chimeric antibodies, autoimmunity, natural antibodies/immune response, anti-idiotypes, and hybridomas secreting interesting growth factors. Immunoregulatory molecules, including T cell hybridomas, will also be featured.

Editorial Board

Editor-in-Chief

Mark C. Glassy, PhD
UC San Diego
Moores Cancer Center
Translational Neuro-Oncology Laboratory

La Jolla, CA
USA
Tel.: +1 858 566 9490
Email: markglassy@aol.com 

Editorial Board

Robert M. Anthony, PhD
Massachusetts General Hospital, Center for Immunology & Inflammatory Diseases, Boston
USA

Dimitrios P. Bogdanos, MBA, MD, PhD
University of Thessaly, Department of Rheumatology and Clinical Immunology, Thessaly
Greece

Dennis R. Burton, PhD
The Scripps Research Institute, Department of Immunology & Microbial Science - IMM2, La Jolla
USA

Paul J. Carter, PhD
Genentech, Inc., Department of Antibody Engineering, San Francisco
USA

Stefan Dübel, PhD
Technische Universitat Braunschweig, Braunschweig
Germany

Gilad Halpert, PhD
Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, Tel-Hashomer
Israel

Michael Hust, PhD
Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Braunschweig
Germany

Angray S. Kang, BSc (Hons), PhD
Queen Mary University of London, Centre for Oral Immunobiology and Regenerative Medicine, Bart's and London Medical and Dental School, London
United Kingdom

Renate Kunert, PhD
Universität für Bodenkultur, Department of Biotechnology, Vienna
Austria

Alois B. Lang, PhD
GeNeuro SA, Geneva
Switzerland

James W Larrick, MD, PhD
Regenerative Sciences Institute, Sunnyvale
USA

Julian Ma, FDS RCS(Ed), PhD
Institute for Infection and Immunity, St. Georges University of London, London
United Kingdom

James D. Marks, MD, PhD
San Francisco General Hospital, Department of Anesthesia, San Francisco
USA

Sherie L. Morrison, PhD
UCLA, Department of Microbiology, Immunology and Molecular Genetics, Los Angeles
USA

David Naor, PhD
The Hebrew University of Jerusalem, Faculty of Medicine, The Lautenberg Center of Immunology and Cancer Research, Jerusalem
Israel

Carlo Perricone, MD, PhD
University of Perugia, Department of Medicine and Surgery, Perugia
Italy

Andreas A. Plückthun, PhD
University of Zurich, Department of Biochemistry, Zurich
Switzerland

Matthew D. Scharff, PhD
Albert Einstein College of Medicine, Department of Cell Biology, Bronx, USA

Yehuda Shoenfeld, MD., FRCP, MaACR
Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, Tel-Hashomer
Israel

Sachdev Sidhu, PhD
University of Toronto, The Donnelly Centre, Toronto
Canada

Leonidas Stamatatos, PhD
Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle
USA

Michael Steinitz, PhD
The Hebrew University, Department of Pathology, Jerusalem, Israel

Mohammad Taheri, PhD
Shahid Beheshti University of Medical Sciences, Department of Medical Genetics, Tehran
Iran

Jean-Luc Teillaud, PhD
French Institute of Health and Medical Research (INSERM), Paris
France

Louis M. Weiner, MD
Georgetown Lombardi Comprehensive Cancer Center, Department of Oncology, Washington
USA

Gregory Winter, PhD
Trinity College, Cambridge
United Kingdom

K. Dane Wittrup, PhD
Massachusetts Institute of Technology, Department of Chemical Engineering and Biological Engineering, Cambridge
USA

Susan Zolla-Pazner, PhD
Icahn School of Medicine at Mount Sinai, Departments of Medicine (Division of Infectious Diseases) and Microbiology, New York
USA

Author Guidelines

SUBMISSION OF MANUSCRIPT

By submitting my article to this journal, I agree to the Author Copyright Agreement, the IOS Press Ethics Policy, and the IOS Press Privacy Policy.

Publication Fee
Human Antibodies does not charge a publication fee.

Authors are requested to submit their manuscript electronically to the journal's submission system.

The manuscript should be uploaded as one file with tables and figures included. Please use the journal's manuscript template. Acceptable file formats include Word document or PDF files; in case of large file size, a zip file can be uploaded.

Required files
A .pdf file of the article is required along with the source files of the text, such as MsWord or LaTeX. If using LaTeX, please use the standard article.sty as a style file and also send a .pdf version of the LaTeX file as well as separate files of all figures (if any). See "Preparation of manuscripts" for the required file formats. LaTeX packages should be compiled into .zip or .rar files.

Color figures
It is possible to have figures printed in color, provided the cost of their reproduction is paid for by the author. See Preparation of Manuscripts for the required file formats.

Open access option
IOS Press offers authors open access options for all its journals. If you opt for open access, the article will be freely available from the moment it is published, also in the pre-press module. Article processing charges are paid in the form of an open access fee. Authors will receive an open access order form upon acceptance of their article. Open access is entirely optional.

For more information about the open access options and licenses available in the IOS Press Open Library, and also to check if there are any institutional agreements that you might be eligible for.

PREPARATION OF MANUSCRIPTS

Organization of the paper and style of presentation
Manuscripts must be written in English. Authors whose native language is not English are advised to consult a professional English language editing service or a native English speaker prior to submission.

Manuscripts should be prepared with wide margins and double spacing throughout, including the abstract, footnotes and references. Every page of the manuscript, including the title page, references, tables, etc., should be numbered. However, in the text no reference should be made to page numbers; if necessary, one may refer to sections. Try to avoid the excessive use of italics and bold face.
Manuscripts should be organized in the following order:

  • Title page
  • Body of text (divided by subheadings)
  • Acknowledgements
  • Author contributions
  • Conflict of Interest
  • References
  • Tables
  • Figure captions
  • Figures

Headings and subheadings should be numbered and typed on a separate line, without indentation.

SI units should be used, i.e., the units based on the metre, kilogramme, second, etc.

Title page
The title page should provide the following information:

  • Title (should be clear, descriptive and not too long)
  • Name(s) of author(s) without abbreviation; please indicate who is the corresponding author. Note that no authors will be added or removed post submission, unless the journal editor and all co-authors are informed and are in agreement to this change.
  • Full affiliation(s)
  • Present address of author(s), if different from affiliation
  • Complete address of the corresponding author, including tel. no., email address, and ORCID ID
  • Abstract
  • Keywords.

Abstract
The abstract should be clear, descriptive, self-explanatory and not longer than 200 words, it should also be suitable for publication in abstracting services.
The abstract for research papers should follow the “structured abstract” format. Section labels should be in bold uppercase letters followed by a colon, and each section will begin on a new line.
BACKGROUND:
OBJECTIVE:
METHODS:
RESULTS:
CONCLUSIONS:

Materials and Methods
Experimental subjects
When human subjects are used, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and written consent of each subject, and that the study conforms with The Code of Ethics of the World Medical Association (Declaration of Helsinki), printed in the British Medical Journal (18 July 1964).

When experimental animals are used, the Materials and methods section must briefly but explicitly state measures which were taken to minimize pain or discomfort, e.g. type and dose of anaesthetic used. Experiments should be carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) or with the Guidelines laid down by the NIH in the US, available from the Office of Laboratory Animal Welfare, National Institutes of Health, Department of Health and Human Services, RKLI, Suite 360, MSC 7982, 6705 Rockledge Drive, Bethesda, MD 20892-7982, or online (olaw.nih.gov) regarding the care and use of animals for experimental procedures.

All studies using human or animal subjects should include an explicit statement in the Materials and Methods section identifying the review and approval committee for each study. Editors reserve the right to reject papers if there is doubt whether appropriate procedures have been used.

Acknowledgments
This section should contain all acknowledgments, including any funding source to the research.

Author contributions
For every author, his or her contribution to the manuscript needs to be provided using the following categories:
Conception:
Interpretation or analysis of data:
Preparation of the manuscript:
Revision for important intellectual content:
Supervision:

Conflict of Interest

Statement of any potential conflicts should be clearly identified at the end of the paper. If there is no conflict of interest to declare, you must still include this section and insert the following statement: "The authors declare that they have no conflict of interest."

If an author is also on the Editorial Board of this journal, the following statement should be included in this section: “<AUTHOR> is an Editorial Board Member of this journal, but was not involved in the peer-review process nor had access to any information regarding its peer-review.’’

REFERENCES

Place citations as numbers in square brackets in the text. All publications cited in the text should be presented in an alphabetical list of references at the end of the manuscript in the following style:

[1] B. Newman and E.T. Liu, Perspective on BRCA1, Breast Disease 10 (1998), 3-10.
[2] D.F. Pilkey, Happy conservation laws, in: Neural Stresses, J. Frost, ed., Controlled Press, Georgia, 1995, pp. 332-391.
[3] E. Wilson, Active vibration analysis of thin-walled beams, Ph.D. Dissertation, University of Virginia, 1991.

Footnotes
Footnotes should only be used if absolutely essential. In most cases it is possible to incorporate the information in the text.

If used, they should be numbered in the text, indicated by superscript numbers and kept as short as possible.

Tables
Number as Table 1, Table 2 etc., and refer to all of them in the text.
Each table should be provided on a separate page of the manuscript. Tables should not be included in the text.
Each table should have a brief and self-explanatory title.
Column headings should be brief, but sufficiently explanatory. Standard abbreviations of units of measurement should be added between parentheses.
Vertical lines should not be used to separate columns. Leave some extra space between the columns instead.
Any explanations essential to the understanding of the table should be given in footnotes at the bottom of the table.

Figures
Number figures as Fig. 1, Fig. 2, etc. and refer to all of them in the text.

Each figure should be provided on a separate sheet. Figures should not be included in the text.

Color figures can be included in the print version, provided the cost of their reproduction is paid for by the author. The online version has no extra charges for color figures.

For the file formats of the figures please take the following into account:
- Line art should be have a minimum resolution of 600 dpi, save as EPS or TIFF
- Grayscales (incl. photos) should have a minimum resolution of 300 dpi (no lettering), or 500 dpi (when there is lettering); save as tiff
- Do not save figures as JPEG, this format may lose information in the process
- Do not use figures taken from the Internet, the resolution will be too low for printing
- Do not use color in your figures if they are to be printed in black & white, as this will reduce the print quality (note that in software often the default is color, you should change the settings)
- For figures that should be printed in color, please send a CMYK encoded EPS or TIFF

Figures should be designed with the format of the page of the journal in mind. They should be of such a size as to allow a reduction of 50%.

On maps and other figures where a scale is needed, use bar scales rather than numerical ones, i.e., do not use scales of the type 1:10,000. This avoids problems if the figures need to be reduced.

Each figure should have a self-explanatory caption. The captions to all figures should be typed on a separate sheet of the manuscript.

Photographs are only acceptable if they have good contrast and intensity.

COPYRIGHT

Copyright of your article
Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.

Quoting from other publications
An author, when quoting from someone else's work or when considering reproducing figures or table from a book or journal article, should make sure that he is not infringing a copyright. Although in general an author may quote from other published works, he should obtain permission from the holder of the copyright if he wishes to make substantial extracts or to reproduce tables, plates or other figures. If the copyright holder is not the author of the quoted or reproduced material, it is recommended that the permission of the author should also be sought. Material in unpublished letters and manuscripts is also protected and must not be published unless permission has been obtained. Submission of a paper will be interpreted as a statement that the author has obtained all the necessary permission. A suitable acknowledgement of any borrowed material must always be made.

PROOFS

The corresponding author will receive a PDF proof and is asked to check this proof carefully (the publisher will execute a cursory check only). Corrections other than printer's errors, however, should be avoided. Costs arising from such corrections will be charged to the authors.

PURCHASES

How to order reprints, a PDF file, journals, or IOS Press books
The corresponding author of a contribution to the journal will receive a complimentary PDF Author’s Copy of the article, unless otherwise stated. This PDF copy is watermarked and for personal use only. A free PDF copy will not be provided for conference proceedings and abstract issues. An order form for a PDF file without watermark, reprints or additional journal copies will be provided along with the PDF proof.

If you wish to order reprints of an earlier published article, please contact the publisher for a quotation. IOS Press, Fax: +31 20 687 0019. Email: editorial@iospress.nl.

An author is entitled to 25% discount on IOS Press books. See Author's discount (25%) on all IOS Press book publications.

KUDOS

Authors of published articles (non-prepress, final articles) will be contacted by Kudos. Kudos is a service that helps researchers maximize the impact and visibility of their research. It allows authors to enrich their articles with lay metadata, add links to related materials and promote their articles through the Kudos system to a wider public. Authors will receive no more than three emails: one invitation and a maximum of two reminders to register for the service and link the published article to their profile. Using and registering for Kudos remains entirely optional. For more information, please have a look at our authors section.

HOW TO PROMOTE YOUR WORK

Would you like some pointers on how to help your research achieve a wider reach and greater impact? Please consult our Promotional Toolkit for Authors for tips.

Abstracted/Indexed in

Academic Search
Cambridge Scientific Abstracts
Chemical Abstracts Service (CAS)
CSA Illumina
EBSCO Databases
Embase
Index Medicus
INIST - Institute for Scientific and Technical Information
MEDLINE
PubMed
SciVerse Scopus
SUBIS
Ulrich's Periodicals Directory
Web of Science: Biological Abstracts
Web of Science: BIOSIS Previews

Open Access

By default, articles published in Human Antibodies are available only to institutions and individuals with access rights. However, the journal offers all authors the option to purchase open access publication for their article as part of the IOS Press Open Library. This means that the final published version will be freely available to anyone worldwide, indefinitely, under a Creative Commons license and without the need to purchase access to the article. This is also referred to as “gold” open access.

Gold open access pricing
Authors who choose gold open access publication will be subject to an article publication charge of € 1250 / US$ 1450 for publication under the CC BY-NC 4.0 license or € 1850 / US$ 2080 for publication under the CC BY 4.0 license. Pricing is exclusive of possible taxes. After an article is accepted for publication, the corresponding author will be informed regarding the open access option during the production stages, and will have the opportunity to purchase open access for their article. It could be that the open access fee of an article is waived completely due an institutional agreement IOS Press has with the corresponding authors' institution. Please check the institutional agreements page for details.

Green open access
Authors who do not make use of the gold open access option may still make their article freely available using self-archiving, also referred to as green open access. Authors may make their final accepted manuscript available for free download from their personal or institutional website or institutional archive. This model is free for the author.

PubMedCentral deposits
This journal deposits all open access articles in PubMedCentral (PMC) as part of the IOS Press Open Library. If an author chooses to publish their paper with open access then the publisher will deposit the article in PMC upon publication.

Peer Review Policy

Human Antibodies is a peer-reviewed journal. Articles submitted to the journal undergo a single blind peer review process. This means that the identity of the authors is known to the reviewers but the identity of the reviewers is not communicated to the authors.

All submitted manuscripts are subjected to initial appraisal by the Editor-in-Chief and, if found suitable for further consideration, to rigorous peer review by independent, anonymous expert referees. Reasons to reject a paper in the pre-screening process could for example be because the work does not fall within the aims and scope, the writing is of poor quality, the instructions to authors were not followed or the presented work is not novel.

Papers deemed suitable to the journal will be forwarded to two reviewers. Reviewers are asked to excuse themselves from reviewing a submission if a conflict makes them unable to make an impartial scientific judgment or evaluation. Conflicts of interest include but are not limited to: collaboration with the authors in the past three years; any professional or financial affiliations that may be perceived as a conflict of interest; a history of personal differences with the author(s). The Editor-in-Chief strives to ensure a typical turnaround time of 3 months.

Reviewers are asked to judge a paper on at least:

  • Significance to field
  • Relevance to journal
  • Methodology
  • Data analysis
  • Literature review
  • Writing style/clarity

Based on the received reviews the Editor-in-Chief will write a decision letter:

  1. Accept
  2. Minor revisions required
  3. Major revisions required
  4. Revise and resubmit
  5. Reject

They mean the following:

  1. The manuscript is suitable for publication and only requires minor polishing; thus, no further reviews are requested.
  2. The authors are required to make moderate changes to their manuscript. The manuscript becomes acceptable for publication if the changes proposed by the reviewers and editors are successfully addressed. The revised manuscript will be examined by the Editor-in-Chief and possibly sent back to all (or a selection of) reviewers for a second round of reviews. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
  3. The manuscript cannot be accepted for publication in its current form. However, a major revision addressing all issues raised by the reviewers may be acceptable for publication. The revised manuscript will undergo a full second round of review. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
  4. In its current form, the manuscript is not suitable for publication. A resubmission would require substantial revisions and is only encouraged in special cases. The resubmitted manuscript will be considered as a new submission.
  5. The manuscript is rejected as it is deemed to be out of scope, not relevant, or not meeting the journal’s quality standards in terms of significance, novelty, and/or presentation.

Authors are notified by the Editor-in-Chief, whose decision is final.

Do you Wish to Receive Updates? – If you would like to receive news updates about our journal Human Antibodies (HAB), let us know by signing up at: tiny.cc/HABsignup. View the recent HAB mailing here.

Latest Articles

Discover the contents of the latest journal issue:

Singleton pregnancy losses before gestational week 22 among patients with autoimmune disorders and methylenetetrahydrofolate reductase polymorphisms
Ummuhan Okuducu, Murat Cagan, Hanife Guler Donmez, Mehmet Sinan Beksac

Cytometric analysis and clinical features in a Moroccan cohort with severe combined immunodeficiency
Sara El Fakihi, Aicha El Allam, Hicham Tahoune, Karima Sahmoudi, Houria Bousserhane, Youssef Bakri, Naima El Hafidi, Fouad Seghrouchni

HLA alleles and haplotype frequencies in Iranian population
Bahdar Mahmud Hussen, Soudeh Ghafouri-Fard, Sara Pashmforoush, Mohammad Taghi Akbari, Shahram Arsang-Jang, Naghme Nazer, Amir Ali Hamidieh, Abbas Hajifathali, Marcel E. Dinger, Arezou Sayad, Mohammadreza Ostadali Dehaghi

The seroprevalence of celiac disease in patients with symptoms of irritable bowel syndrome: A cross-sectional study in the north of Iran
Sara Yeganeh, Farahnaz Joukar, Afshin Shafaghi, Mohammad Reza Mahjoub-Jalali, Soheil Hassanipour, Luigi Santacroce, Sara Mavaddati, Fariborz Mansour-Ghanaei

Assessment of specific human antibodies against SARS-CoV-2 receptor binding domain by rapid in-house ELISA
Esraa A.A. Ali, Nahla A. Hussein, Amr E. El-Hakim, Ashraf A. Tabll, Asmaa El-Shershaby, Azza Salamony, Mohamed N.F. Shaheen, Ibrahim Ali, Mahmoud Elshall, Yasser E. Shahein

Sustainable Development Goals

This journal supports IOS Press' actions relating to the Sustainable Development Goals (SDGs) and commits to the Diversity and Inclusion Statement.

dark blue banner for HAB author geo data for SDGs

More information will be available in due course. Check the SDGs page for updates.  

HAB red journal signup banner